In vivo studies showed that the HPV-DC vaccine formulated with GUPS-AuNPs as carriers effectively suppressed tumor growth, elevated the populations of CD4+ T and CD8+ T cells in the spleen, and induced a robust antigen-specific immune response. Here, CD8A is linked to neoplasm.